TSN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tyson Foods Inc (TSN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as analyst upgrades and hedge fund buying, the company's weak financial performance, ongoing antitrust investigation, and lack of strong trading signals suggest a cautious approach. Holding the stock for now is advisable.
The technical indicators are mixed. The MACD is below 0 and negatively contracting, suggesting bearish momentum. The RSI is neutral at 61.327, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 64.382, with resistance at 65.398 and support at 63.366.
Analysts have upgraded the stock recently, with price targets raised to as high as $
Hedge funds are significantly increasing their positions, with a 47960.00% increase in buying activity last quarter.
The company benefits from structural growth in protein demand and operational improvements.
The U.S. Department of Justice has initiated a criminal antitrust investigation into major meatpackers, including Tyson Foods, which could lead to regulatory challenges.
The company's financial performance in Q1 2026 showed a significant decline in net income (-76.32% YoY) and EPS (-76.24% YoY), along with a drop in gross margin (-14.14% YoY).
Stock trend analysis shows a 50% chance of a -8.01% decline in the next month.
In Q1 2026, Tyson Foods reported a revenue increase of 6.17% YoY to $14.46 billion. However, net income dropped significantly to $85 million (-76.32% YoY), EPS fell to $0.24 (-76.24% YoY), and gross margin declined to 7.35% (-14.14% YoY). These metrics indicate financial struggles despite revenue growth.
Recent analyst ratings are mixed but leaning positive. Piper Sandler upgraded the stock to Overweight with a price target of $75, citing competitive disruptions in beef and chicken as potential catalysts. Mizuho initiated coverage with an Outperform rating and a $72 price target, highlighting structural growth in protein demand. However, JPMorgan and BTG Pactual remain cautious, with JPMorgan lowering its price target to $65 and BTG Pactual issuing a Sell rating with a $58 price target.
